-

23rd World Breast Health Congress丨Prof. Jian Yin: Building on Local Practice to Advance the Standardization and Internationalization of Oncoplastic Breast Surgery
Breast cancer is one of the most common malignancies affecting women worldwide. With the widespread adoption of early screening and diagnosis and continued advances in comprehensive treatment, survival rates among patients with breast cancer have improved significantly. As a result, the need for postoperative quality of life and physical and psychological rehabilitation has become increasingly…
-

23rd World Breast Health Congress丨Prof. Ying Wang: Deepening International Collaboration to Promote Equitable Development of Breast Health in China
Breast cancer has become the most commonly diagnosed malignancy among women worldwide. In recent years, China has continued to explore new approaches to breast cancer screening, clinical diagnosis and treatment, rehabilitation management, and public health education, accumulating extensive experience and steadily improving its overall prevention and treatment capabilities. Recently, the 23rd World Breast Health Congress…
-

Sadia Khan: Insights from US Training in Oncoplastic Breast-Conserving Surgery丨2026 Beijing Breast Cancer Forum
The 2026 Beijing Breast Cancer Forum and Beijing Breast Reconstruction Forum was held in Beijing from June 23 to 28, 2026. The meeting brought together leading breast surgery experts from China and abroad to discuss advances in breast cancer diagnosis and treatment, breast reconstruction, and oncoplastic breast-conserving surgery. As part of the “International Perspectives ·…
-

2026 Northern Breast Cancer Forum丨Prof. Xueli Mo: From Single-Target Therapy to the ADC Era — Tracing the Evolution of HER2-Positive Advanced Breast Cancer
From trastuzumab opening the door to HER2-targeted therapy, to dual-targeted regimens becoming the cornerstone of first-line treatment, and now to ADCs reshaping survival outcomes, the treatment history of HER2-positive advanced breast cancer reflects the continuous evolution of precision oncology. The 2026 Northern Breast Cancer Forum was successfully held in Qingdao from July 25 to 26.…
-

2026 Northern Breast Cancer Forum丨Prof. Yunjiang Liu: From Endocrine Therapy to Precision Targeted Therapy — Milestones in HR-Positive Breast Cancer
Hormone receptor (HR)-positive breast cancer accounts for approximately 70% of all breast cancer cases. From the early exploration of ovarian ablation more than a century ago, to tamoxifen ushering in the era of endocrine therapy, and then to CDK4/6 inhibitor-based combinations reshaping the treatment landscape of advanced disease, each major therapeutic breakthrough has profoundly altered…
-

First Global Guideline for the Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine Published
Recently, the China Association of Chinese Medicine (CACM) Group Standard, Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine was officially released in Beijing. As the world’s first guiding standard for the integrated evaluation of evidence on the efficacy of traditional Chinese medicine (TCM), the standard was jointly developed under the leadership of…
-

EHA 2026 | Prof. Stephen Ansell & Dr. Zhihui Li: Decoding the Future of Hodgkin Lymphoma
How has PD-1 blockade transformed the treatment of Hodgkin lymphoma? Can biomarkers such as CD30 and 9p24.1 amplification further refine precision therapy? And what lessons can HL teach us about the future of T-cell lymphoma? At EHA 2026, Dr. Zhihui Li of Beijing Gaobo BoRen Hospital joined Prof. Stephen Ansell of Mayo Clinic for an…
-

EHA 2026丨Prof. Stephen Ansell and Dr. Zhihui Li: Exploring the Immunobiology and Precision Treatment of Hodgkin Lymphoma
Crossing borders, exchanging insights, and exploring the frontiers of hematology. During the 2026 Congress of the European Hematology Association (EHA), Oncology Frontier – Hematology Frontier invited Dr. Zhihui Li, Director of Beijing Gaobo BoRen Hospital, and Prof. Stephen Ansell of Mayo Clinic for an in-depth discussion on the tumor immune microenvironment and precision treatment of…